Skip to main content

Osteopontin deficiency ameliorates Alport pathology by preventing tubular metabolic deficits.

Publication ,  Journal Article
Ding, W; Yousefi, K; Goncalves, S; Goldstein, BJ; Sabater, AL; Kloosterboer, A; Ritter, P; Lambert, G; Mendez, AJ; Shehadeh, LA
Published in: JCI Insight
March 22, 2018

Alport syndrome is a rare hereditary renal disorder with no etiologic therapy. We found that osteopontin (OPN) is highly expressed in the renal tubules of the Alport mouse and plays a causative pathological role. OPN genetic deletion ameliorated albuminuria, hypertension, tubulointerstitial proliferation, renal apoptosis, and hearing and visual deficits in the Alport mouse. In Alport renal tubules we found extensive cholesterol accumulation and increased protein expression of dynamin-3 (DNM3) and LDL receptor (LDLR) in addition to dysmorphic mitochondria with defective bioenergetics. Increased pathological cholesterol influx was confirmed by a remarkably increased uptake of injected DiI-LDL cholesterol by Alport renal tubules, and by the improved lifespan of the Alport mice when crossed with the Ldlr-/- mice with defective cholesterol influx. Moreover, OPN-deficient Alport mice demonstrated significant reduction of DNM3 and LDLR expression. In human renal epithelial cells, overexpressing DNM3 resulted in elevated LDLR protein expression and defective mitochondrial respiration. Our results suggest a potentially new pathway in Alport pathology where tubular OPN causes DNM3- and LDLR-mediated enhanced cholesterol influx and impaired mitochondrial respiration.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JCI Insight

DOI

EISSN

2379-3708

Publication Date

March 22, 2018

Volume

3

Issue

6

Location

United States

Related Subject Headings

  • Triglycerides
  • Transcriptome
  • Smegmamorpha
  • Receptors, LDL
  • Osteopontin
  • Nephritis, Hereditary
  • Mitochondria
  • Mice, Knockout
  • Mice, Inbred C57BL
  • Mice, Inbred BALB C
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ding, W., Yousefi, K., Goncalves, S., Goldstein, B. J., Sabater, A. L., Kloosterboer, A., … Shehadeh, L. A. (2018). Osteopontin deficiency ameliorates Alport pathology by preventing tubular metabolic deficits. JCI Insight, 3(6). https://doi.org/10.1172/jci.insight.94818
Ding, Wen, Keyvan Yousefi, Stefania Goncalves, Bradley J. Goldstein, Alfonso L. Sabater, Amy Kloosterboer, Portia Ritter, Guerline Lambert, Armando J. Mendez, and Lina A. Shehadeh. “Osteopontin deficiency ameliorates Alport pathology by preventing tubular metabolic deficits.JCI Insight 3, no. 6 (March 22, 2018). https://doi.org/10.1172/jci.insight.94818.
Ding W, Yousefi K, Goncalves S, Goldstein BJ, Sabater AL, Kloosterboer A, et al. Osteopontin deficiency ameliorates Alport pathology by preventing tubular metabolic deficits. JCI Insight. 2018 Mar 22;3(6).
Ding, Wen, et al. “Osteopontin deficiency ameliorates Alport pathology by preventing tubular metabolic deficits.JCI Insight, vol. 3, no. 6, Mar. 2018. Pubmed, doi:10.1172/jci.insight.94818.
Ding W, Yousefi K, Goncalves S, Goldstein BJ, Sabater AL, Kloosterboer A, Ritter P, Lambert G, Mendez AJ, Shehadeh LA. Osteopontin deficiency ameliorates Alport pathology by preventing tubular metabolic deficits. JCI Insight. 2018 Mar 22;3(6).

Published In

JCI Insight

DOI

EISSN

2379-3708

Publication Date

March 22, 2018

Volume

3

Issue

6

Location

United States

Related Subject Headings

  • Triglycerides
  • Transcriptome
  • Smegmamorpha
  • Receptors, LDL
  • Osteopontin
  • Nephritis, Hereditary
  • Mitochondria
  • Mice, Knockout
  • Mice, Inbred C57BL
  • Mice, Inbred BALB C